华仁药业(300110) - 2025 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2025 reached ¥352,374,010.10, an increase of 16.62% compared to the same period last year[2] - Net profit attributable to shareholders decreased by 22.72% to ¥17,246,910.68 in Q3 2025, and by 42.87% to ¥54,579,793.85 for the year-to-date[2] - Basic earnings per share for Q3 2025 were ¥0.0146, down 22.75% year-on-year[2] - Total operating revenue for the current period is RMB 976,270,444.55, a decrease of 9.07% compared to RMB 1,073,621,963.53 in the previous period[21] - Net profit for the period was ¥57,398,016.43, down from ¥100,471,124.16, representing a decline of about 43%[23] - Basic and diluted earnings per share decreased to ¥0.0462 from ¥0.0808, a drop of approximately 42.5%[23] Assets and Liabilities - Total assets as of September 30, 2025, were ¥3,396,808,707.61, a decrease of 0.91% from the end of the previous year[2] - Total assets decreased to RMB 3,396,808,707.61 from RMB 3,428,120,079.39, a decline of 0.9%[19] - Total liabilities decreased to RMB 1,970,961,247.11 from RMB 2,054,191,740.04, a reduction of 4.0%[19] - Non-current assets decreased slightly to RMB 2,234,426,391.53 from RMB 2,243,141,469.80, a decline of 0.3%[18] - The total equity attributable to the parent company increased to RMB 1,355,366,082.86 from RMB 1,300,786,289.01, a growth of 4.2%[19] Cash Flow and Financial Activities - Cash flow from operating activities for the year-to-date was ¥256,623,163.38, down 10.08% compared to the same period last year[2] - Cash flow from operating activities generated ¥256,623,163.38, compared to ¥285,386,815.04 in the previous period, a decrease of about 10%[25] - Cash and cash equivalents increased to RMB 222,890,633.82 from RMB 163,813,254.90, representing a growth of 36%[18] - Cash and cash equivalents at the end of the period increased to ¥186,178,965.82 from ¥119,922,385.96, reflecting a net increase of approximately 55.4%[26] - The net cash flow from financing activities for the year-to-date was -¥175,892,477.20, a decrease of 51.18% compared to the previous year[10] - Financing activities produced a net cash outflow of ¥175,892,477.20, an improvement from an outflow of ¥360,267,179.13 in the previous period[25] Inventory and Prepayments - Inventory decreased by 20.64% to ¥252,561,995.35, attributed to improved inventory management[6] - Inventory decreased significantly to RMB 252,561,995.35 from RMB 318,237,397.12, a reduction of 20.6%[18] - The company reported a significant increase in prepayments by 63.04% to ¥33,075,466.47, mainly due to increased operational prepayments[6] Financial Performance Metrics - Financial expenses decreased by 21.95% to ¥33,783,971.27 for the year-to-date, primarily due to reduced interest expenses from loan scale compression[8] - The weighted average return on equity for Q3 2025 was 1.28%, an increase of 0.47% from the previous year[2] - Tax expenses decreased to ¥5,879,952.99 from ¥13,939,611.92, a reduction of approximately 57.8%[22] - Other income increased to ¥2,180,154.49 from ¥582,194.48, marking a significant rise of about 274%[22] - The company reported a credit impairment loss of ¥-13,968,652.22, worsening from ¥-913,335.01 in the previous period[22]